3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
7
Phase 1
4
Phase 4
2
Phase 3
1
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Non-Small-Cell Lung
699
Breast Neoplasms
629
Neoplasms
582
Leukemia, Myeloid, Acute
481
Colorectal Neoplasms
455
Multiple Myeloma
444
Melanoma
424
Prostatic Neoplasms
383
Neoplasm Metastasis
370
Pancreatic Neoplasms
361
Recurrence
347
Lymphoma
340
Ovarian Neoplasms
322
Lung Neoplasms
297
Lymphoma, Non-Hodgkin
295
Leukemia
287
Glioblastoma
275
Precursor Cell Lymphoblastic Leukemia-Lymphoma
249
Stomach Neoplasms
246
Leukemia, Lymphocytic, Chronic, B-Cell
235
Carcinoma, Hepatocellular
231
Squamous Cell Carcinoma of Head and Neck
219
Lymphoma, Large B-Cell, Diffuse
217
Myelodysplastic Syndromes
212
Carcinoma, Renal Cell
210
Lymphoma, Follicular
183
Head and Neck Neoplasms
172
Brain Neoplasms
169
Triple Negative Breast Neoplasms
167
Lymphoma, Mantle-Cell
167
Interventions
pembrolizumab
1
olaparib
1
lenvatinib
1
enzalutamide
1
belzutifan
1
Prednisone
1
Etoposide
1
Docetaxel
1
Dexamethasone
1
Carboplatin
1
Abiraterone Acetate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Interventional
×
Metastatic Castration-Resistant Prostate Cancer
×
Clear all
NCT02861573
2026-02-17
KEYNOTE-365
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
1,200 enrolled